[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2019207554A1 - Extraction of compounds from cannabis biomass using food-grade solvent - Google Patents

Extraction of compounds from cannabis biomass using food-grade solvent Download PDF

Info

Publication number
WO2019207554A1
WO2019207554A1 PCT/IB2019/053466 IB2019053466W WO2019207554A1 WO 2019207554 A1 WO2019207554 A1 WO 2019207554A1 IB 2019053466 W IB2019053466 W IB 2019053466W WO 2019207554 A1 WO2019207554 A1 WO 2019207554A1
Authority
WO
WIPO (PCT)
Prior art keywords
biomass
oil
carrier fluid
slurry
solvent
Prior art date
Application number
PCT/IB2019/053466
Other languages
French (fr)
Other versions
WO2019207554A4 (en
Inventor
Steven Splinter
Tomasz Popek
Harmandeep KAUR
Anna BAKOWSKA-BARCZAK
Brian Sloley
Original Assignee
Radient Technologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radient Technologies Inc. filed Critical Radient Technologies Inc.
Publication of WO2019207554A1 publication Critical patent/WO2019207554A1/en
Publication of WO2019207554A4 publication Critical patent/WO2019207554A4/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D11/00Solvent extraction
    • B01D11/02Solvent extraction of solids
    • B01D11/0211Solvent extraction of solids in combination with an electric or magnetic field
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D11/00Solvent extraction
    • B01D11/02Solvent extraction of solids
    • B01D11/0288Applications, solvents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D11/00Solvent extraction
    • B01D11/02Solvent extraction of solids
    • B01D11/0292Treatment of the solvent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D11/00Solvent extraction
    • B01D11/02Solvent extraction of solids
    • B01D11/0215Solid material in other stationary receptacles
    • B01D11/0223Moving bed of solid material
    • B01D11/0226Moving bed of solid material with the general transport direction of the solids parallel to the rotation axis of the conveyor, e.g. worm

Definitions

  • the present disclosure is generally related to a method for extracting pharmacologically active compounds. More particularly, the present disclosure relates to extraction of Delta-9- Tetrahydrocannabinol (THC) and related compounds from cannabis biomass.
  • THC Delta-9- Tetrahydrocannabinol
  • Cannabis is a genus belonging to the family of cannabaceae. Three common species include Cannabis sativa, Cannabis indica, and Cannabis ruderalis. The genus has been indigenous to Central Asia and the Indian subcontinent. Cannabis has a long history being used for medicinal, therapeutic, and recreational purposes. The importance of cannabis in therapeutics is emphasized by the ever-increasing number of research publication related to the new indications for cannabis. For example, pharmaceutical research companies are presently developing new natural cannabinoid formulations and delivery systems to meet various regulatory requirements. Cannabis is known, for example, to be capable of relieving nausea (such as that accompanying
  • cannabis or “cannabis biomass” encompasses the Cannabis sativa plant and also variants thereof, including subspecies sativa, indica and ruderalis, cannabis cultivars, and cannabis chemovars (varieties characterised by chemical composition), which naturally contain different amounts of the individual cannabinoids, and also plants which are the result of genetic crosses.
  • cannabis chemovars variants characterised by chemical composition
  • the term “cannabis biomass” is to be interpreted accordingly as encompassing plant material derived from one or more cannabis plants.
  • Cannabis biomass contains a unique class of terpeno-phenolic compounds known as cannabinoids or phytocannabinoids, which have been extensively studied since the discovery of the chemical structure of tetrahydrocannabinol (Delta-9-THC), commonly known as THC. Over 113 phytocannabinoids have been identified.
  • cannabinoids are generally produced by glandular trichomes that occur on most aerial surfaces of the plant.
  • the cannabinoids are biosynthesized in the plant in addic forms known as acidic cannabinoids.
  • the acidic cannabinoids may be slowly decarboxylated during drying of harvested plant material. Decarboxylation may be hastened by heating the cannabis biomass, such as when the cannabis biomass is smoked or vaporized.
  • the principle cannabinoids present in cannabis are the Delta-9-tetrahydrocannabinolic acid (Delta-9-THCA) and cannabidiolic acid (CBDA).
  • the Delta-9-THCA does not have its own psychoactive properties as is, but may be decarboxylated to Delta-9-tetrahydrocannabinol (Delta-9- THC), which is the most potent psychoactive cannabinoid among known cannabinoids.
  • the neutral form of CBDA is cannabidiol (CBD), which is a major cannabinoid substituent in hemp cannabis.
  • CBD is non-psychoactive and is widely known to have therapeutic potential for a variety of medical conditions.
  • the proportion of cannabinoids in the plant may vary from species to spedes, as well as vary within the same species at different times and seasons. Furthermore, the proportion of cannabinoids in a plant may further depend upon soil, climate, and harvesting methods. Thus, based on the proportion of the cannabinoids present in a plant variety, the psychoactive and medicinal effects obtained from different plant varieties may vary.
  • a specific variety of cannabis may be considered more effective or potent than others (e.g ., in providing the desired physiological effect at a desired level in an individual).
  • some specific combinations of pharmacologically active compounds in a cannabis variety may be more desirable in comparison to other varieties.
  • the retention of the full mix of cannabinoids present in the original plant may be desirable for some varieties, while other varieties may be preferred in altered form due to the variances in the specific cannabinoid composition and concentrations. Such variance is further exacerbated by the presence of certain terpenoid or phenolic compounds, which may have pharmacological activity of their own and which may be desired at different concentrations in different combinations.
  • compounds may be extracted from cannabis by using conventional methods of extraction, such as maceration, decoction, or solvent extraction.
  • conventional methods may suffer from various limitations and disadvantages (e.g ., extraction times may be very high so as to be impractical to scale).
  • subjecting the biomass to a prolonged extraction process may risk modification of the plant profile, negative effects on terpenes, or otherwise cause other undesirable effects that lower the quality or purity of the end product.
  • Traditional methods of extraction may therefore hamper quality and purity of the final product.
  • final concentrated or purified active compounds are often diluted or dispersed into an oil, fat or other lipid-based excipient or carrier to a desired concentration for certain uses (e.g., in a pharmaceutical, food, or cosmetic formulation).
  • SFE supercritical fluid extraction
  • SFE is also inefficient and therefore not conducive to high throughputs, as well as environmentally damaging (e.g ., producing large amounts of the greenhouse gas carbon dioxide as a by-product).
  • traditional methods of extracting inactive cannabinoids from a raw cannabis biomass typically involve subjecting the raw cannabis biomass to a heating process in order to decarboxylate the cannabinoids prior to extraction.
  • the cannabinoids are generally extracted using traditional solvent, such as alkane hydrocarbons (e.g., hexane or butane), or alcohols (e.g., ethanol).
  • alkane hydrocarbons e.g., hexane or butane
  • alcohols e.g., ethanol
  • Such traditional solvents may be expensive and undesirable to end-users. Notwithstanding that the solvent may be completely removed from the end product, end-users may be wary of the risk presented by the use of solvent for health and environmental reasons.
  • ethanol When used as a solvent, ethanol has many of the benefits of SCF extraction without requiring high pressures in the extractor. Further, ethanol extraction has shown efficiency comparable to hydrocarbon extraction (e.g., butane), which has an increased level of safety concerns (e.g., solvent combustion) and health-related concerns as customers may perceive a hydrocarbon-extracted product as less healthful.
  • hydrocarbon extraction e.g., butane
  • the ethanol extraction technique may be used for selective extraction of pharmacologically relevant chemicals from various natural, as well as synthetic, matrices under environmentally safe operation.
  • the selective extraction may be performed, for example, using a composite device having several components, such as a high- pressure pump, an extraction vessel, a back-pressure regulator, analyte collection vessel, and a source of solvent (e.g., C2H5OH).
  • a composite device having several components, such as a high- pressure pump, an extraction vessel, a back-pressure regulator, analyte collection vessel, and a source of solvent (e.g., C2H5OH).
  • the ethanol extraction technique may be used for commercial applications that may involve biologically produced materials. Such ethanol extraction may be relevant to extraction of biological compounds in cases where a low temperature processing, high mass transfer rates, and negligible carry over of solvent into a final product may be desired.
  • Embodiments of the present invention provide extraction methods that remove the need for an intermediate solvent. Instead, a carrier fluid suitable for inclusion in a final formulation may be used as the solvent for cannabis extraction. Thus, a novel approach is provided for cannabis extraction using alternate method to differentiate the product in the market by way of decreased risk (e.g. r from use of non-food-grade solvents).
  • Exemplary methods for extracting pharmacologically active compounds from a biomass may therefore include preparing cannabis biomass, adding a carrier fluid to the prepared cannabis biomass to form a slurry where the carrier fluid is a solvent that is suitable for inclusion in a final formulation, and extracting target compounds from the slurry using a continuous flow extraction apparatus, and separating a spent biomass from the carrier fluid by a downstream process.
  • Such extracted target compounds may include Delta-9-THC, Delta-9-THCA, CBDA, CBD, other cannabinoids, and terpenes.
  • FIG. 1 is a block diagram representation of an exemplary system for extracting pharmacologically active compounds from biomass.
  • FIG. 2 is a flow chart illustrating an exemplary method for extracting pharmacologically active compounds from biomass.
  • FIG. 3A and FIG. 3B are tables that provide a comparison of different solvents that may be used in biomass extraction of pharmacologically active compounds under different conditions to provide different results.
  • FIG. 4 is a flow chart illustrating an alternative exemplary method for extracting pharmacologically active compounds from biomass.
  • Embodiments of the present disclosure include systems and methods for extracting pharmacologically active compounds from a biomass may therefore include preparing cannabis biomass, adding a carrier fluid to the prepared cannabis biomass to form a slurry where the carrier fluid is a solvent that is suitable for inclusion in a final formulation, extracting target compounds from the slurry using a continuous flow extraction apparatus, and separating a spent biomass from the carrier fluid by a downstream process.
  • Such extracted target compounds may include Delta-9- THC, Delta-9-THCA, CBDA, CBD, other cannabinoids, and terpenes.
  • FIG. 1 is a block diagram representation of an exemplary system 100 for extracting pharmacologically active compounds from biomass
  • FIG. 2 is a flow chart illustrating an exemplary method 200 for extracting pharmacologically active compounds from biomass.
  • System 100 of FIG. 1 includes a raw biomass holding chamber 102, into which a raw biomass may be provided in step 202 of FIG. 2.
  • a raw biomass may be present in form of dried, ground, non-decarboxylated flowers (buds) of cannabis plants. Any part of the cannabis biomass that contains cannabinoids can be used or included in the raw biomass that is provided to raw biomass holding chamber 102. In some embodiment, average particle size of the raw biomass may lie between 0.5 - 10 mm.
  • the raw biomass may contain target compounds that need to be extracted.
  • the raw biomass may be heated to approximately 125° C for approximately 45 minutes to decarboxylate the cannabinoid carboxylic acids into neutral cannabinoid forms.
  • the mass of decarboxylated cannabis following such treatment may get reduced (e.g ., 11.7% weight loss).
  • the raw biomass may be dried, non-decarboxylated cannabis biomass.
  • the raw biomass may be fresh, non-dried, non-decarboxylated cannabis biomass.
  • the raw biomass may be sampled and analyzed in sampling chamber 120.
  • the raw biomass may be analyzed to determine cannabinoid content, and a cannabinoid profile (of the specific cannabinoids and concentrations thereof) of the sampled raw biomass may be generated.
  • a cannabinoid profile (of the specific cannabinoids and concentrations thereof) of the sampled raw biomass may be generated.
  • Such analysis may be performed using an Ultra High Performance Liquid Chromatography coupled with Mass Spectroscopy (UPLC-MS) detection technique.
  • UPLC-MS Ultra High Performance Liquid Chromatography coupled with Mass Spectroscopy
  • a terpene profile of the raw biomass may be determined using a Gas Chromatography-Mass Spectroscopy Detection (GC-MS).
  • the sampling techniques may help in determining the cannabinoid content and the cannabinoid profile of the raw biomass (i.e ., THCA, THC, CBDA, CBD, and total cannabinoids present
  • the raw biomass may be ground into small particles to obtain a prepared biomass in biomass preparation chamber 104.
  • the prepared biomass may then be provided from biomass preparation chamber 104 to a prepared biomass holding chamber 106.
  • the prepared biomass may be used to form a slurry in step 208.
  • the slurry may be formed in a slurry formation chamber 108 where one or more solvents may be added to the prepared biomass from a solvent holding chamber 110.
  • the solvent added to the prepared biomass may be selected with different dielectric and solvent parameter properties.
  • the solvent may be, for example, a Medium Chain Triglyceride (MCT) (e.g ., coconut oil) or other edible and food-grade solvent or emulsifier used to standardize active compounds in pharmaceutical, nutraceutical, functional, food, or cosmetic formulations. Such solvent may therefore further be pharmaceutical- grade and.or cosmetics-grade.
  • MCT Medium Chain Triglyceride
  • Such solvent may therefore further be pharmaceutical- grade and.or cosmetics-grade.
  • the solvent may be a polyunsaturated fatty acid (PUFA), com oil, safflower oil, borage oil, flax oil, canola oil, cottonseed oil, soybean oil, olive oil, sunflower oil, coconut oil, palm oil, monoglycerides, diglycerides, triglycerides, medium chain or long chain triglycerides, ledthin, limonene, essential oils of spices, herbs or other plants, fish oil, glycerol, glycols, or any other, or mixtures thereof.
  • MCT may be used as the solvent. It may be understood that certain solvents may be preferable from a marketing standpoint and/or cost standpoint.
  • the solvent-to-raw biomass ratio may be maintained at approximately 5-10 l/kg to ease the pumping operation of the slurry. In an embodiment, the solvent-to-raw biomass ratio may be maintained as low as possible so as to maximize the concentration of the PUFA), com oil, safflower oil, borage oil, flax oil, canola
  • the slurry may be transferred from the slurry formation chamber 108 to an extraction chamber 112 where such slurry is subject to heat at step 210.
  • the slurry may be transported using a set of mechanical conveyors (e.g ., slurry pump, screw conveyor or worm gear).
  • the slurry may be subjected to a thermal process, such as provided by a microwave generator 114. It may be understood that the selected solvent(s) may require a specific temperature to facilitate efficient transportation through the set of mechanical conveyors.
  • the solvent e.g., MCT
  • thermal energy e.g., from microwave generator 114
  • the slurry may be transported into an extraction chamber 112 through a tube.
  • Extraction chamber 112 may include a portion that is microwave transparent, which may allow microwaves (e.g., generated using a magnetron of microwave generator 112) to pass through and heat the slurry inside the extraction chamber 112.
  • the slurry may be heated within the extraction chamber 112 to a certain temperature by exposing the slurry to the microwave to a predefined time with a predefined microwave energy density range.
  • the slurry may be heated to a temperature range of 25 - 75° C with a contact time of 1 - 30 minutes, and microwave energy density range of 0.1 - 10 kW/kg. Such heating may facilitate the extraction of various
  • the now-spent biomass and solvent(s) may be transferred to separation chamber 116, where the slurry is subject to filtration and separation at step 212.
  • Such filtration and separation within filtration unit 116 may result in isolating the slurry components from each other: the spent biomass and the solvent(s) containing the extracted compounds.
  • the spent biomass and the solvent(s) containing the extracted compounds may be transferred into spent biomass storage unit 118 and solvent recovery chamber 122, respectively.
  • the separation process may be performed using one or more of several methods, such as filtration, centrifugation, and other similar processes. In a preferred embodiment, the separation process may include use of a filter press.
  • the spent biomass may be sampled at step 214.
  • Sampling of the spent biomass may be performed in a sampling chamber 120.
  • the spent biomass may be sampled and analyzed to determine remaining cannabinoid content and cannabinoid profile.
  • the spent biomass may be sampled and analyzed using several methods. The analysis may be performed using an Ultra High Performance Liquid Chromatography coupled with Mass Spectroscopy detection (UPLC-MS). Further, terpene profile of the raw biomass may be determined using a Gas Chromatography-Mass Spectroscopy Detection (GC-MS).
  • UPLC-MS Ultra High Performance Liquid Chromatography coupled with Mass Spectroscopy detection
  • terpene profile of the raw biomass may be determined using a Gas Chromatography-Mass Spectroscopy Detection (GC-MS).
  • GC-MS Gas Chromatography-Mass Spectroscopy Detection
  • waste spent biomass may be incinerated or mixed with a deactivating agent by a disposal system 128.
  • a deactivating agent In one case, clay may be used as the deactivating agent.
  • an extract/solvent mixture may first be separated from the spent biomass, and the solvent may then be separated from the extract/solvent mixture and recovered by a solvent recovery chamber 122 at step 216. As a result, a desolvenized extract may be obtained.
  • the solvent may be recovered from the extract/solvent mixture by a distillation or evaporation process, so that the solvent may be used in another extraction process.
  • the carrier fluid used to form the slurry e.g., "MCT solvent”
  • MCT solvent now containing extracted pharmacologically active compounds
  • the MCT solvent may simply be separated from the spent biomass and incorporated directly into a formulation without the need for extensive solvent removal (e.g., vacuum evaporation or distillation).
  • the MCT solvent containing pharmacologically active compounds may then be combined with additional carrier fluid or excipients or other additives to create a specified formulation at step 218.
  • the formulation— combination of the MCT solvent (including extracts) with additional carrier fluid— may be performed in a formulation chamberl24.
  • the resulting formulation product may then be provided to a product holding chamber 126.
  • the MCT solvent containing pharmacologically active compounds may be recirculated for re-use as solvent in a slurry with freshly prepared (non-extracted) biomass at step 208. Such recirculation and re-use may repeat multiple times so as to increase the concentration of the pharmacologically active compounds in the carrier fluid to a desired level (as determined from sampling chamberl20).
  • the MCT solvent containing pharmacologically active compounds could be subjected to a controlled decarboxylation process.
  • sampling of the formulation product may be performed at step 220.
  • Sampling of the formulated extract may be performed in the sampling chamber 120.
  • the formulated extract may comprise Delta-9-THC, Delta-9-THCA, CBDA, CBD, other cannabinoids, terpenes, or other medicinal value compounds.
  • the formulated extract may be sampled and analyzed using several methods. In a preferred embodiment, analysis of the formulated extract may be done to determine cannabinoid content and cannabinoid profile. The analysis may be performed using an Ultra High Performance Liquid Chromatography coupled with Mass
  • terpene profile of the raw biomass may be determined using a Gas Chromatography-Mass Spectroscopy Detection (GC-MS).
  • GC-MS Gas Chromatography-Mass Spectroscopy Detection
  • FIG. 3A and FIG. 3B are tables that provide a comparison of different solvents that may be used in biomass extraction of pharmacologically active compounds under different conditions to provide different results. Such comparison may include, for example, test data obtained regarding usage of typical solvents for a biomass extraction process and usage of edible or food grade oil for a biomass extraction process.
  • FIG. 3A pertains to slurries that may be formed using such solvents as, for example, alcohols (e.g ., ethanol), alkanes (e.g., pentane), or any suitable organic solvent as the extraction solvent (e.g., suitable organic solvent and MCT oil or any suitable carrier fluid).
  • solvents as, for example, alcohols (e.g ., ethanol), alkanes (e.g., pentane), or any suitable organic solvent as the extraction solvent (e.g., suitable organic solvent and MCT oil or any suitable carrier fluid).
  • the extracted solids may be separated from the extract/solvent mixture (miscella) in separation chamber 116, and provided to spent biomass holding chamber 118. Residual solvent held up in the marc may be recovered in solvent recovery chamber 122, and the spent biomass solids may be collected for disposal by way of disposal system 128.
  • the miscella may be concentrated by a vacuum evaporator (e.g., in separation chamber 116), and the mixture may be condensed and collected for re-use (e.g., solvent recovery chamber 122).
  • An example of extraction parameters may include the solvent-to-solid ratio and the extraction temperature used (e.g., as provided by microwave generator 114) .
  • the extraction efficiency (percent recovery of available cannabinoids) may be the percentage recovery of THCA recovered in the final extract, in order to show loss of quantities of THCA during the extraction process.
  • the extraction may involve heating using microwave energy.
  • FIG. 3B pertains to slurries that may be extracted using MCT oil or any suitable carrier fluid.
  • the extracted solids (marc) may be separated from the solvent (miscella) in separation chamber 116 and provided to spent biomass holding chamber 118. Residual solvent may be held up in the marc, recovered, and provided to solvent recovery chamber 122 .
  • the spent biomass solids may be collected for disposal by disposal system 128.
  • the extraction efficiency (percent recovery of available cannabinoids) may be the percentage recovery of THCA recovered in the final extract, in order to show loss of quantities of THCA during the extraction process. Exposing these solvent mixtures to a microwave field (e.g ., from microwave generator 114) may produce higher recovery percentages of cannabinoids, and/or may allow for a quicker extraction time.
  • FIG. 4 is a flow chart illustrating an alternative exemplary method 400 for extracting pharmacologically active compounds from biomass.
  • the functions noted in the method blocks illustrated herein may occur out of the order illustrated in the drawings. For example, two blocks shown in succession may in fact be executed substantially concurrently or in a different order, depending upon the functionality involved.
  • the process descriptions or blocks in flow charts should be understood as representing decisions made by a hardware structure, such as a state machine.
  • a prepared biomass may be provided.
  • the prepared biomass may comprise cannabis plant components that include target compounds for extraction.
  • the prepared biomass may be obtained by processing raw biomass into particles of a desired size.
  • the raw biomass may be present in the form of dried, ground, and non-decarboxylated flowers (buds) of cannabis plants.
  • a slurry may be formed by adding one or more solvents to the prepared biomass.
  • the solvent added to the prepared biomass mass may be selected with different dielectric and solvent parameter properties.
  • the solvent may be a Medium Chain Triglyceride (MCT) or different edible and food-grade solvents or emulsifier used to standardize active compounds in pharmaceutical, nutraceutical, functional, food, or cosmetic formulations.
  • MCT Medium Chain Triglyceride
  • the solvent may be a polyunsaturated fatty acid (PUFA), com oil, safflower oil, borage oil, flax oil, canola oil, cottonseed oil, soybean oil, olive oil, sunflower oil, monoglycerides, diglycerides, triglycerides, lecithin, limonene, essential oils of spices, herbs or other plants, fish oil, glycerol, glycols, or any other, or mixtures thereof.
  • PUFA polyunsaturated fatty acid
  • the slurry may be transferred to an extractor for extraction of the target components.
  • the slurry may be transported using a set of mechanical conveyors.
  • the slurry may be heated to a certain temperature by exposing the slurry to microwaves, for a predefined time with a predefined microwave energy range.
  • the solvent may be recovered back to the slurry form and a de-solvenized extract may be obtained.
  • the solvent may be recovered from the extract mixture by distillation process.
  • the solvent recovered may be used in another extraction process.
  • MCT solvent used to form the slurry with the raw biomass may not need a recovery, and may be directly inputted into a formulation or other downstream process.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Fats And Perfumes (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A method of extracting pharmacologically active compounds from cannabis biomass is disclosed. The method comprises providing a raw biomass containing target compounds. Slurry is prepared by adding a solvent to the prepared biomass. In a preferred embodiment, the solvent may be a medium-chain triglyceride, such as coconut oil, or an edible and food-grade solvent or emulsifier used to standardize active compounds in pharmaceutical, nutraceutical, functional food, or cosmetic formulations. In some embodiments, the solvent may be a polyunsaturated fatty acid (PUFA), com oil, safflower oil, borage oil, flax oil, canola oil, cottonseed oil, soybean oil, olive oil, sunflower oil, monoglycerides, diglycerides, triglycerides, lecithin, limonene, essential oils of spices, herbs or other plants, fish oil, glycerol, glycols, or any other, or mixtures thereof. Various pharmacologically active compounds could be extracted from the slurry by processing in a continuous flow extractor. Successively, the solvent containing various pharmacologically active compounds may be separated from a spent biomass.

Description

EXTRACTION OF COMPOUNDS FROM CANNABIS BIOMASS USING
FOOD-GRADE SOLVENT
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present patent application claims the priority benefit of U.S. provisional patent application number 62/663,540 filed April 27, 2018, the disclosure of which is incorporated by reference herein.
BACKGROUND OF THE INVENTION
1. Field Of The Disclosure
[0002] The present disclosure is generally related to a method for extracting pharmacologically active compounds. More particularly, the present disclosure relates to extraction of Delta-9- Tetrahydrocannabinol (THC) and related compounds from cannabis biomass.
2. Description of the Related Art
[0003] Cannabis is a genus belonging to the family of cannabaceae. Three common species include Cannabis sativa, Cannabis indica, and Cannabis ruderalis. The genus has been indigenous to Central Asia and the Indian subcontinent. Cannabis has a long history being used for medicinal, therapeutic, and recreational purposes. The importance of cannabis in therapeutics is emphasized by the ever-increasing number of research publication related to the new indications for cannabis. For example, pharmaceutical research companies are presently developing new natural cannabinoid formulations and delivery systems to meet various regulatory requirements. Cannabis is known, for example, to be capable of relieving nausea (such as that accompanying
chemotherapy), pain, vomiting, spasticity in multiple sclerosis, and increase hunger in anorexia.
[0004] The term cannabis or "cannabis biomass" encompasses the Cannabis sativa plant and also variants thereof, including subspecies sativa, indica and ruderalis, cannabis cultivars, and cannabis chemovars (varieties characterised by chemical composition), which naturally contain different amounts of the individual cannabinoids, and also plants which are the result of genetic crosses. The term "cannabis biomass" is to be interpreted accordingly as encompassing plant material derived from one or more cannabis plants.
[0005] Cannabis biomass contains a unique class of terpeno-phenolic compounds known as cannabinoids or phytocannabinoids, which have been extensively studied since the discovery of the chemical structure of tetrahydrocannabinol (Delta-9-THC), commonly known as THC. Over 113 phytocannabinoids have been identified. Such cannabinoids are generally produced by glandular trichomes that occur on most aerial surfaces of the plant. The cannabinoids are biosynthesized in the plant in addic forms known as acidic cannabinoids. The acidic cannabinoids may be slowly decarboxylated during drying of harvested plant material. Decarboxylation may be hastened by heating the cannabis biomass, such as when the cannabis biomass is smoked or vaporized.
[0006] The principle cannabinoids present in cannabis are the Delta-9-tetrahydrocannabinolic acid (Delta-9-THCA) and cannabidiolic acid (CBDA). The Delta-9-THCA does not have its own psychoactive properties as is, but may be decarboxylated to Delta-9-tetrahydrocannabinol (Delta-9- THC), which is the most potent psychoactive cannabinoid among known cannabinoids. The neutral form of CBDA is cannabidiol (CBD), which is a major cannabinoid substituent in hemp cannabis. CBD is non-psychoactive and is widely known to have therapeutic potential for a variety of medical conditions. The proportion of cannabinoids in the plant may vary from species to spedes, as well as vary within the same species at different times and seasons. Furthermore, the proportion of cannabinoids in a plant may further depend upon soil, climate, and harvesting methods. Thus, based on the proportion of the cannabinoids present in a plant variety, the psychoactive and medicinal effects obtained from different plant varieties may vary.
[0007] Depending upon the psychoactive and medicinal effects obtained from different varieties of the cannabis plant or the different methods of cultivation for cannabis, a specific variety of cannabis may be considered more effective or potent than others ( e.g ., in providing the desired physiological effect at a desired level in an individual). Similarly, some specific combinations of pharmacologically active compounds in a cannabis variety may be more desirable in comparison to other varieties. When preparing cannabis plant extracts, the retention of the full mix of cannabinoids present in the original plant may be desirable for some varieties, while other varieties may be preferred in altered form due to the variances in the specific cannabinoid composition and concentrations. Such variance is further exacerbated by the presence of certain terpenoid or phenolic compounds, which may have pharmacological activity of their own and which may be desired at different concentrations in different combinations.
[0008] Historical delivery methods have involved smoking ( e.g.r combusting) the dried cannabis plant material. Smoking results, however, in adverse effects on the respiratory system via the production of potentially toxic substances. In addition, smoking is an inefficient mechanism that delivers a variable mixture of active and inactive substances, many of which may be undesirable. Alternative delivery methods such as ingesting typically require extracts of the cannabis biomass (also known as cannabis concentrates or cannabis oils). Often, cannabis extracts are formulated using any convenient pharmacologically acceptable diluents, carriers or exdpients to produce a composition. Raw cannabis biomass may also be more susceptible to possible biological contaminants such as fungi and bacteria than extracts.
[0009] Previously, compounds may be extracted from cannabis by using conventional methods of extraction, such as maceration, decoction, or solvent extraction. Such conventional methods may suffer from various limitations and disadvantages ( e.g ., extraction times may be very high so as to be impractical to scale). For example, subjecting the biomass to a prolonged extraction process may risk modification of the plant profile, negative effects on terpenes, or otherwise cause other undesirable effects that lower the quality or purity of the end product. Traditional methods of extraction may therefore hamper quality and purity of the final product. Further, final concentrated or purified active compounds are often diluted or dispersed into an oil, fat or other lipid-based excipient or carrier to a desired concentration for certain uses (e.g., in a pharmaceutical, food, or cosmetic formulation).
[0010] Other methods such as supercritical fluid extraction (SFE) make use of supercritical fluids to selectively remove compounds from solid, semisolid, and liquid matrices in a batch process. SFE is, however, dangerous and requires very high pressures to be employed (> 70 atm).
In addition, SFE is also inefficient and therefore not conducive to high throughputs, as well as environmentally damaging ( e.g ., producing large amounts of the greenhouse gas carbon dioxide as a by-product).
[0011] Meanwhile, traditional solvent extraction methods used for extraction of cannabinoids tend to be complex, multi-step processes that involve the use of large amounts of organic solvents and multiple steps of selective solvent removal, separation, and refinement. Such processes therefore may require expensive equipment to evaporate and recover as much of the solvent as possible and to remove most of the residual solvent from the final product and extracted spent solid residue. The flammable nature of the organic solvents employed also necessitates expensive control systems and procedures to limit combustion risk and environmental impact and to ensure worker safety. Further, the need to remove solvents from treated biomass gives rise to significant power requirements that in turn represent additional resources, as well as contributing
significantly to environmental pollution derived from the production of said energy.
[0012] Meanwhile, traditional methods of extracting inactive cannabinoids from a raw cannabis biomass typically involve subjecting the raw cannabis biomass to a heating process in order to decarboxylate the cannabinoids prior to extraction. The cannabinoids are generally extracted using traditional solvent, such as alkane hydrocarbons (e.g., hexane or butane), or alcohols (e.g., ethanol). Such traditional solvents may be expensive and undesirable to end-users. Notwithstanding that the solvent may be completely removed from the end product, end-users may be wary of the risk presented by the use of solvent for health and environmental reasons.
[0013] When used as a solvent, ethanol has many of the benefits of SCF extraction without requiring high pressures in the extractor. Further, ethanol extraction has shown efficiency comparable to hydrocarbon extraction (e.g., butane), which has an increased level of safety concerns (e.g., solvent combustion) and health-related concerns as customers may perceive a hydrocarbon-extracted product as less healthful. The ethanol extraction technique may be used for selective extraction of pharmacologically relevant chemicals from various natural, as well as synthetic, matrices under environmentally safe operation. The selective extraction may be performed, for example, using a composite device having several components, such as a high- pressure pump, an extraction vessel, a back-pressure regulator, analyte collection vessel, and a source of solvent (e.g., C2H5OH). The ethanol extraction technique may be used for commercial applications that may involve biologically produced materials. Such ethanol extraction may be relevant to extraction of biological compounds in cases where a low temperature processing, high mass transfer rates, and negligible carry over of solvent into a final product may be desired.
[0014] Thus, there is a need for improved methods and systems of direct extraction of bioactive components from a given biomass, as well as a need to provide concentration of such bioactive components to the final desired concentration in a dispersion or solution medium while reducing or eliminating intermediate steps and use of organic solvents including those derived from petroleum or petrochemical products.
SUMMARY OF THE CLAIMED INVENTION
[0015] Embodiments of the present invention provide extraction methods that remove the need for an intermediate solvent. Instead, a carrier fluid suitable for inclusion in a final formulation may be used as the solvent for cannabis extraction. Thus, a novel approach is provided for cannabis extraction using alternate method to differentiate the product in the market by way of decreased risk ( e.g.r from use of non-food-grade solvents).
[0016] Exemplary methods for extracting pharmacologically active compounds from a biomass may therefore include preparing cannabis biomass, adding a carrier fluid to the prepared cannabis biomass to form a slurry where the carrier fluid is a solvent that is suitable for inclusion in a final formulation, and extracting target compounds from the slurry using a continuous flow extraction apparatus, and separating a spent biomass from the carrier fluid by a downstream process. Such extracted target compounds may include Delta-9-THC, Delta-9-THCA, CBDA, CBD, other cannabinoids, and terpenes.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] FIG. 1 is a block diagram representation of an exemplary system for extracting pharmacologically active compounds from biomass.
[0018] FIG. 2 is a flow chart illustrating an exemplary method for extracting pharmacologically active compounds from biomass.
[0019] FIG. 3A and FIG. 3B are tables that provide a comparison of different solvents that may be used in biomass extraction of pharmacologically active compounds under different conditions to provide different results.
[0020] FIG. 4 is a flow chart illustrating an alternative exemplary method for extracting pharmacologically active compounds from biomass.
DETAILED DESCRIPTION
[0021] Embodiments of the present disclosure include systems and methods for extracting pharmacologically active compounds from a biomass may therefore include preparing cannabis biomass, adding a carrier fluid to the prepared cannabis biomass to form a slurry where the carrier fluid is a solvent that is suitable for inclusion in a final formulation, extracting target compounds from the slurry using a continuous flow extraction apparatus, and separating a spent biomass from the carrier fluid by a downstream process. Such extracted target compounds may include Delta-9- THC, Delta-9-THCA, CBDA, CBD, other cannabinoids, and terpenes.
[0022] Method of extracting pharmacologically active compounds from cannabis biomass will now be explained with reference to various units shown in the block diagram of FIG. 1 and the flow chart 200 of FIG. 2. FIG. 1 is a block diagram representation of an exemplary system 100 for extracting pharmacologically active compounds from biomass, and FIG. 2 is a flow chart illustrating an exemplary method 200 for extracting pharmacologically active compounds from biomass.
[0023] System 100 of FIG. 1 includes a raw biomass holding chamber 102, into which a raw biomass may be provided in step 202 of FIG. 2. Such raw biomass may be present in form of dried, ground, non-decarboxylated flowers (buds) of cannabis plants. Any part of the cannabis biomass that contains cannabinoids can be used or included in the raw biomass that is provided to raw biomass holding chamber 102. In some embodiment, average particle size of the raw biomass may lie between 0.5 - 10 mm. The raw biomass may contain target compounds that need to be extracted. In one embodiment, the raw biomass may be heated to approximately 125° C for approximately 45 minutes to decarboxylate the cannabinoid carboxylic acids into neutral cannabinoid forms. The mass of decarboxylated cannabis following such treatment may get reduced ( e.g ., 11.7% weight loss). In an embodiment, the raw biomass may be dried, non-decarboxylated cannabis biomass. In another embodiment, the raw biomass may be fresh, non-dried, non-decarboxylated cannabis biomass.
[0024] Successively in step 204, the raw biomass may be sampled and analyzed in sampling chamber 120. In a preferred embodiment, the raw biomass may be analyzed to determine cannabinoid content, and a cannabinoid profile (of the specific cannabinoids and concentrations thereof) of the sampled raw biomass may be generated. Such analysis may be performed using an Ultra High Performance Liquid Chromatography coupled with Mass Spectroscopy (UPLC-MS) detection technique. Further, a terpene profile of the raw biomass may be determined using a Gas Chromatography-Mass Spectroscopy Detection (GC-MS). The sampling techniques may help in determining the cannabinoid content and the cannabinoid profile of the raw biomass ( i.e ., THCA, THC, CBDA, CBD, and total cannabinoids present in the raw biomass).
[0025] Further in step 206, the raw biomass may be ground into small particles to obtain a prepared biomass in biomass preparation chamber 104. The prepared biomass may then be provided from biomass preparation chamber 104 to a prepared biomass holding chamber 106.
[0026] The prepared biomass may be used to form a slurry in step 208. The slurry may be formed in a slurry formation chamber 108 where one or more solvents may be added to the prepared biomass from a solvent holding chamber 110. The solvent added to the prepared biomass may be selected with different dielectric and solvent parameter properties. The solvent may be, for example, a Medium Chain Triglyceride (MCT) ( e.g ., coconut oil) or other edible and food-grade solvent or emulsifier used to standardize active compounds in pharmaceutical, nutraceutical, functional, food, or cosmetic formulations. Such solvent may therefore further be pharmaceutical- grade and.or cosmetics-grade. Further, the solvent may be a polyunsaturated fatty acid (PUFA), com oil, safflower oil, borage oil, flax oil, canola oil, cottonseed oil, soybean oil, olive oil, sunflower oil, coconut oil, palm oil, monoglycerides, diglycerides, triglycerides, medium chain or long chain triglycerides, ledthin, limonene, essential oils of spices, herbs or other plants, fish oil, glycerol, glycols, or any other, or mixtures thereof. In a preferred embodiment, MCT may be used as the solvent. It may be understood that certain solvents may be preferable from a marketing standpoint and/or cost standpoint. The solvent-to-raw biomass ratio may be maintained at approximately 5-10 l/kg to ease the pumping operation of the slurry. In an embodiment, the solvent-to-raw biomass ratio may be maintained as low as possible so as to maximize the concentration of the
pharmacologically active compounds in the extract product.
[0027] Thereafter, the slurry may be transferred from the slurry formation chamber 108 to an extraction chamber 112 where such slurry is subject to heat at step 210. The slurry may be transported using a set of mechanical conveyors ( e.g ., slurry pump, screw conveyor or worm gear). In the extraction chamber 112, the slurry may be subjected to a thermal process, such as provided by a microwave generator 114. It may be understood that the selected solvent(s) may require a specific temperature to facilitate efficient transportation through the set of mechanical conveyors.
In a preferred embodiment, the solvent (e.g., MCT) is heated with thermal energy (e.g., from microwave generator 114) to a temperature that meets or exceeds the solvent7 s melting point. In one case, the slurry may be transported into an extraction chamber 112 through a tube. Extraction chamber 112 may include a portion that is microwave transparent, which may allow microwaves (e.g., generated using a magnetron of microwave generator 112) to pass through and heat the slurry inside the extraction chamber 112. The slurry may be heated within the extraction chamber 112 to a certain temperature by exposing the slurry to the microwave to a predefined time with a predefined microwave energy density range. In a preferred embodiment, the slurry may be heated to a temperature range of 25 - 75° C with a contact time of 1 - 30 minutes, and microwave energy density range of 0.1 - 10 kW/kg. Such heating may facilitate the extraction of various
(pharmacologically active) compounds from the prepared biomass into the solvent.
[0028] Post heating the slurry and extraction of compounds from the biomass, the now-spent biomass and solvent(s) may be transferred to separation chamber 116, where the slurry is subject to filtration and separation at step 212. Such filtration and separation within filtration unit 116 may result in isolating the slurry components from each other: the spent biomass and the solvent(s) containing the extracted compounds. Once isolated, the spent biomass and the solvent(s) containing the extracted compounds may be transferred into spent biomass storage unit 118 and solvent recovery chamber 122, respectively. The separation process may be performed using one or more of several methods, such as filtration, centrifugation, and other similar processes. In a preferred embodiment, the separation process may include use of a filter press.
[0029] In an embodiment, the spent biomass may be sampled at step 214. Sampling of the spent biomass may be performed in a sampling chamber 120. The spent biomass may be sampled and analyzed to determine remaining cannabinoid content and cannabinoid profile. The spent biomass may be sampled and analyzed using several methods. The analysis may be performed using an Ultra High Performance Liquid Chromatography coupled with Mass Spectroscopy detection (UPLC-MS). Further, terpene profile of the raw biomass may be determined using a Gas Chromatography-Mass Spectroscopy Detection (GC-MS). The sampling and analytical techniques may help in determining cannabinoid content and profile of the raw biomass (e.g., THCA, THC, CBDA, CBD, and total cannabinoids).
[0030] Post sampling and analysis of the spent biomass, waste spent biomass may be incinerated or mixed with a deactivating agent by a disposal system 128. In one case, clay may be used as the deactivating agent.
[0031] In a traditional solvent (e.g., ethanol) extraction process, an extract/solvent mixture may first be separated from the spent biomass, and the solvent may then be separated from the extract/solvent mixture and recovered by a solvent recovery chamber 122 at step 216. As a result, a desolvenized extract may be obtained. The solvent may be recovered from the extract/solvent mixture by a distillation or evaporation process, so that the solvent may be used in another extraction process.
[0032] In a preferred embodiment, however, the carrier fluid used to form the slurry (e.g., "MCT solvent") with the raw biomass may not be subject to solvent separation and removal, providing an improvement over the traditional extraction method. The MCT solvent— now containing extracted pharmacologically active compounds— may simply be separated from the spent biomass and incorporated directly into a formulation without the need for extensive solvent removal (e.g., vacuum evaporation or distillation). Post separation from the spent biomass, the MCT solvent containing pharmacologically active compounds may then be combined with additional carrier fluid or excipients or other additives to create a specified formulation at step 218. The formulation— combination of the MCT solvent (including extracts) with additional carrier fluid— may be performed in a formulation chamberl24. The resulting formulation product may then be provided to a product holding chamber 126.
[0033] In an embodiment, the MCT solvent containing pharmacologically active compounds may be recirculated for re-use as solvent in a slurry with freshly prepared (non-extracted) biomass at step 208. Such recirculation and re-use may repeat multiple times so as to increase the concentration of the pharmacologically active compounds in the carrier fluid to a desired level (as determined from sampling chamberl20). In an embodiment, the MCT solvent containing pharmacologically active compounds could be subjected to a controlled decarboxylation process.
[0034] Thereafter, sampling of the formulation product may be performed at step 220.
Sampling of the formulated extract may be performed in the sampling chamber 120. The formulated extract may comprise Delta-9-THC, Delta-9-THCA, CBDA, CBD, other cannabinoids, terpenes, or other medicinal value compounds. The formulated extract may be sampled and analyzed using several methods. In a preferred embodiment, analysis of the formulated extract may be done to determine cannabinoid content and cannabinoid profile. The analysis may be performed using an Ultra High Performance Liquid Chromatography coupled with Mass
Spectroscopy detection (UPLC-MS). Further, terpene profile of the raw biomass may be determined using a Gas Chromatography-Mass Spectroscopy Detection (GC-MS). Such sampling techniques may help in determining cannabinoid content and profile of the raw biomass (i.e., THCA, THC, CBDA, CBD, and total cannabinoids).
[0035] FIG. 3A and FIG. 3B are tables that provide a comparison of different solvents that may be used in biomass extraction of pharmacologically active compounds under different conditions to provide different results. Such comparison may include, for example, test data obtained regarding usage of typical solvents for a biomass extraction process and usage of edible or food grade oil for a biomass extraction process.
[0036] FIG. 3A pertains to slurries that may be formed using such solvents as, for example, alcohols ( e.g ., ethanol), alkanes (e.g., pentane), or any suitable organic solvent as the extraction solvent (e.g., suitable organic solvent and MCT oil or any suitable carrier fluid). The extracted solids (marc) may be separated from the extract/solvent mixture (miscella) in separation chamber 116, and provided to spent biomass holding chamber 118. Residual solvent held up in the marc may be recovered in solvent recovery chamber 122, and the spent biomass solids may be collected for disposal by way of disposal system 128. The miscella may be concentrated by a vacuum evaporator (e.g., in separation chamber 116), and the mixture may be condensed and collected for re-use (e.g., solvent recovery chamber 122). An example of extraction parameters may include the solvent-to-solid ratio and the extraction temperature used (e.g., as provided by microwave generator 114) . The extraction efficiency (percent recovery of available cannabinoids) may be the percentage recovery of THCA recovered in the final extract, in order to show loss of quantities of THCA during the extraction process. The extraction may involve heating using microwave energy.
[0037] FIG. 3B pertains to slurries that may be extracted using MCT oil or any suitable carrier fluid. The extracted solids (marc) may be separated from the solvent (miscella) in separation chamber 116 and provided to spent biomass holding chamber 118. Residual solvent may be held up in the marc, recovered, and provided to solvent recovery chamber 122 . The spent biomass solids may be collected for disposal by disposal system 128. The extraction efficiency (percent recovery of available cannabinoids) may be the percentage recovery of THCA recovered in the final extract, in order to show loss of quantities of THCA during the extraction process. Exposing these solvent mixtures to a microwave field ( e.g ., from microwave generator 114) may produce higher recovery percentages of cannabinoids, and/or may allow for a quicker extraction time.
[0038] Whereas FIG. 2 illustrates one exemplary method, FIG. 4 is a flow chart illustrating an alternative exemplary method 400 for extracting pharmacologically active compounds from biomass. It should also be noted that in some implementations, the functions noted in the method blocks illustrated herein may occur out of the order illustrated in the drawings. For example, two blocks shown in succession may in fact be executed substantially concurrently or in a different order, depending upon the functionality involved. In addition, the process descriptions or blocks in flow charts should be understood as representing decisions made by a hardware structure, such as a state machine.
[0039] At step 402, a prepared biomass may be provided. The prepared biomass may comprise cannabis plant components that include target compounds for extraction. The prepared biomass may be obtained by processing raw biomass into particles of a desired size. The raw biomass may be present in the form of dried, ground, and non-decarboxylated flowers (buds) of cannabis plants.
[0040] At step 404, a slurry may be formed by adding one or more solvents to the prepared biomass. The solvent added to the prepared biomass mass may be selected with different dielectric and solvent parameter properties. The solvent may be a Medium Chain Triglyceride (MCT) or different edible and food-grade solvents or emulsifier used to standardize active compounds in pharmaceutical, nutraceutical, functional, food, or cosmetic formulations. Further, the solvent may be a polyunsaturated fatty acid (PUFA), com oil, safflower oil, borage oil, flax oil, canola oil, cottonseed oil, soybean oil, olive oil, sunflower oil, monoglycerides, diglycerides, triglycerides, lecithin, limonene, essential oils of spices, herbs or other plants, fish oil, glycerol, glycols, or any other, or mixtures thereof.
[0041] At step 406, the slurry may be transferred to an extractor for extraction of the target components. The slurry may be transported using a set of mechanical conveyors. The slurry may be heated to a certain temperature by exposing the slurry to microwaves, for a predefined time with a predefined microwave energy range.
[0042] At step 408, the solvent may be recovered back to the slurry form and a de-solvenized extract may be obtained. The solvent may be recovered from the extract mixture by distillation process. The solvent recovered may be used in another extraction process. In a preferred embodiment, MCT solvent used to form the slurry with the raw biomass may not need a recovery, and may be directly inputted into a formulation or other downstream process.
[0043] The foregoing detailed description of the technology has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the technology to the precise form disclosed. Many modifications and variations are possible in light of the above teaching. The described embodiments were chosen in order to best explain the principles of the technology, its practical application, and to enable others skilled in the art to utilize the technology in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the technology be defined by the claim.

Claims

CLAIMS WHAT IS CLAIMED IS:
1. A method of extracting pharmacologically active compounds from a biomass, the method comprising:
preparing raw cannabis biomass, wherein the prepared cannabis biomass comprises particles;
adding a carrier fluid to the prepared cannabis biomass to form a slurry, wherein the added carrier fluid includes a food-grade solvent;
extracting target compounds from the slurry using a continuous flow extraction apparatus, wherein the target compounds comprise cannabinoids and terpenes; and
separating a spent biomass from the carrier fluid by a downstream process, wherein the separated carrier fluid now further includes the extracted target compounds.
2. The method of claim 1, wherein preparing the raw cannabis biomass comprises at least one of milling, grinding, or sorting plant matter in the raw cannabis biomass into the particles.
3. The method of claim 1, wherein the carrier fluid includes at least one of medium chain triglyceride, polyunsaturated fatty acid, com oil, safflower oil, borage oil, flax oil, canola oil, cottonseed oil, soybean oil, olive oil, sunflower oil, monoglycerides, di glycerides, triglycerides, lecithin, limonene, essential oils of spices, herbs or other plants, fish oil, glycerol, and glycols.
4. The method of claim 1, wherein the downstream process comprises at least one of concentration, separation, isolation, and formulation.
5. The method of claim 1, further comprising combining the separated carrier fluid with a new raw cannabis biomass to form a new slurry.
6. The method of claim 1, further comprising analyzing the separated carrier fluid, and generating a cannabinoid profile based on the analysis, the cannabinoid profile identifying a plurality of different cannabinoids within the analyzed carrier fluid, each different cannabinoid associated with an identified concentration.
7. The method of claim 6, further comprising recirculating the separated carrier fluid to combine with a new raw cannabis biomass to form a new slurry until a desired profile is reached.
8. The method of claim 1, wherein extracting the target compounds comprises heating the slurry.
9. The method of claim 8, wherein the slurry is heated to at least a melting point temperature of the carrier fluid.
10. The method of claim 8, wherein heating the slurry comprises applying microwave energy.
11. The method of claim 1, further comprising decarboxylating the separated carrier fluid.
12. The method of claim 11, wherein decarboxylating the separated carrier fluid comprises subjecting the separated carrier fluid to controlled decarboxylation in accordance with a desired level of conversion of the cannabinoids to one or more neutral forms.
13. The method of claim 1, wherein the carrier fluid is further pharmaceutical-grade or cosmetics- grade.
14. The method of claim 1, wherein the carrier fluid further includes an organic solvent mixed with the food-grade solvent.
15. A system of extracting pharmacologically active compounds from a biomass, the system comprising:
a biomass preparation chamber where raw cannabis biomass is prepared, wherein the prepared cannabis biomass comprises particles;
a slurry formation chamber that receives the prepared cannabis biomass from the biomass preparation chamber, wherein a carrier fluid is added to the prepared cannabis biomass to form a slurry, wherein the added carrier fluid includes a food-grade solvent;
a continuous flow extraction apparatus that extracts target compounds from the slurry using a, wherein the target compounds comprise cannabinoids and terpenes; and
a separation chamber that separates a spent biomass from the carrier fluid by a
downstream process, wherein the separated carrier fluid now further includes the extracted target compounds.
16. The system of claim 15, wherein the biomass chamber prepares the raw cannabis biomass by at least one of milling, grinding, or sorting plant matter in the raw cannabis biomass into the particles.
17. The system of claim 15, wherein the carrier fluid includes at least one of medium chain triglyceride, polyunsaturated fatty acid, com oil, safflower oil, borage oil, flax oil, canola oil, cottonseed oil, soybean oil, olive oil, sunflower oil, monoglycerides, di glycerides, triglycerides, lecithin, limonene, essential oils of spices, herbs or other plants, fish oil, glycerol, and glycols.
18. The system of claim 15, wherein the downstream process comprises at least one of
concentration, separation, isolation, and formulation.
19. The system of claim 15, further comprising a conveyor that recirculates the separated carrier fluid to combine with a new raw cannabis biomass and form a new slurry.
20. The system of claim 15, further comprising a sampling chamber that analyzes the separated carrier fluid, and generates a cannabinoid profile based on the analysis, the cannabinoid profile identifying a plurality of different cannabinoids within the analyzed carrier fluid, each different cannabinoid associated with an identified concentration.
21. The system of claim 20, further comprising a conveyor that recirculates the separated carrier fluid to combine with a new raw cannabis biomass to form a new slurry until a desired profile is reached.
22. The system of claim 15, further comprising a microwave generator, wherein the microwave generator facilitates extracting the target compounds by heating the slurry.
23. The system of claim 22, wherein the slurry is heated to at least a melting point temperature of the carrier fluid.
24. The system of claim 22, wherein heating the slurry comprises applying microwave energy from the microwave generator.
25. The system of claim 15, wherein the separated carrier fluid is further decarboxylated.
26. The system of claim 25, wherein decarboxylating the separated carrier fluid comprises subjecting the separated carrier fluid to controlled decarboxylation in accordance with a desired level of conversion of the cannabinoids to one or more neutral forms.
27. The system of claim 15, wherein the carrier fluid is further pharmaceutical-grade or cosmetics- grade.
28. The system of claim 15, wherein the carrier fluid further includes an organic solvent mixed with the food-grade solvent.
PCT/IB2019/053466 2018-04-27 2019-04-27 Extraction of compounds from cannabis biomass using food-grade solvent WO2019207554A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862663540P 2018-04-27 2018-04-27
US62/663,540 2018-04-27

Publications (2)

Publication Number Publication Date
WO2019207554A1 true WO2019207554A1 (en) 2019-10-31
WO2019207554A4 WO2019207554A4 (en) 2019-12-19

Family

ID=67770537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/053466 WO2019207554A1 (en) 2018-04-27 2019-04-27 Extraction of compounds from cannabis biomass using food-grade solvent

Country Status (1)

Country Link
WO (1) WO2019207554A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU102018B1 (en) * 2020-08-26 2022-02-28 K D Pharma Bexbach Gmbh Extraction process and mixture of substances
WO2022043422A1 (en) * 2020-08-26 2022-03-03 K.D. Pharma Bexbach Gmbh Extraction method and mixture of substances

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445034B1 (en) * 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
US20130338234A1 (en) * 2012-06-19 2013-12-19 Radient Technologies Inc. Method for direct extraction and concentration of naturally-derived active compounds
WO2015070167A1 (en) * 2013-11-11 2015-05-14 The Werc Shop, LLC Solvent-free processing, system and methods
US9808494B2 (en) * 2015-01-22 2017-11-07 Rm3 Labs, Llc Process for the extraction of cannabinoids from cannabis using lipids as an extraction solvent
US20180000857A1 (en) * 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
WO2018061009A1 (en) * 2016-09-29 2018-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Method for selective extraction of cannabinoids from a plant source
US20180343812A1 (en) * 2017-05-31 2018-12-06 Insectergy, Llc Cannabis farming systems and methods
US20180369191A1 (en) * 2017-06-27 2018-12-27 Enviro BioMedical Laboratories Inc. Blended cannabis compounds and methods of making the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445034B1 (en) * 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
US20130338234A1 (en) * 2012-06-19 2013-12-19 Radient Technologies Inc. Method for direct extraction and concentration of naturally-derived active compounds
WO2015070167A1 (en) * 2013-11-11 2015-05-14 The Werc Shop, LLC Solvent-free processing, system and methods
US9808494B2 (en) * 2015-01-22 2017-11-07 Rm3 Labs, Llc Process for the extraction of cannabinoids from cannabis using lipids as an extraction solvent
US20180000857A1 (en) * 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
WO2018061009A1 (en) * 2016-09-29 2018-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Method for selective extraction of cannabinoids from a plant source
US20180343812A1 (en) * 2017-05-31 2018-12-06 Insectergy, Llc Cannabis farming systems and methods
US20180369191A1 (en) * 2017-06-27 2018-12-27 Enviro BioMedical Laboratories Inc. Blended cannabis compounds and methods of making the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRIGHENTI, V. ET AL.: "Development of a New Extraction Technique and HPLC Method for the Analysis of Non-Psychoactive Cannabinoids in Fibre-Type Cannabis Sativa L. (Hemp", JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, vol. 143, 4 June 2017 (2017-06-04), pages 228 - 236, XP085108189 *
CHANG, C.W. ET AL.: "Microwave-Assisted Extraction of Cannabinoids in Hemp Nut Using Response Surface Methodology: Optimization and Comparative Study", MOLECULES, vol. 22, no. 11, 3 November 2017 (2017-11-03), pages 1894, XP055631518 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU102018B1 (en) * 2020-08-26 2022-02-28 K D Pharma Bexbach Gmbh Extraction process and mixture of substances
WO2022043422A1 (en) * 2020-08-26 2022-03-03 K.D. Pharma Bexbach Gmbh Extraction method and mixture of substances

Also Published As

Publication number Publication date
WO2019207554A4 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
WO2019211797A1 (en) Method of decarboxylating acidic cannabinoids in cannabis extract suspended within a carrier fluid
Chemat et al. Green extraction of natural products. Origins, current status, and future challenges
Herrero et al. Supercritical fluid extraction: Recent advances and applications
Rombaut et al. Green extraction processes of natural products as tools for biorefinery
Da Porto et al. Microwave pretreatment of Moringa oleifera seed: Effect on oil obtained by pilot-scale supercritical carbon dioxide extraction and Soxhlet apparatus
Nguyen et al. Extraction of oil from Moringa oleifera kernels using supercritical carbon dioxide with ethanol for pretreatment: Optimization of the extraction process
US9895404B1 (en) Cannabidiol extraction plant and processes
Novello et al. Extraction, chemical characterization and antioxidant activity of andiroba seeds oil obtained from pressurized n-butane
dos Santos Garcia et al. Extraction of Mucuna seed oil using supercritical carbon dioxide to increase the concentration of l-Dopa in the defatted meal
IL258324A (en) Methods for the production of different cannabis product compositions
Johner et al. Developing a supercritical fluid extraction method assisted by cold pressing for extraction of pequi (Caryocar brasiliense)
Górnaś et al. Impact of the extraction technique and genotype on the oil yield and composition of lipophilic compounds in the oil recovered from Japanese quince (Chaenomeles japonica) seeds
Skaltsounis et al. Recovery of high added value compounds from olive tree products and olive processing byproducts
Martinez et al. Extraction techniques for bioactive compounds of cannabis
Li et al. Extraction of oil from grape seeds (Vitis vinifera L.) using recyclable CO2-expanded ethanol
Belayneh et al. Ethanol‐modified supercritical carbon dioxide extraction of the bioactive lipid components of Camelina sativa seed
AHMADI et al. Evaluation and analysis of the ultrasound-assisted extracted tomato seed oil
Drinić et al. Application of conventional and high-pressure extraction techniques for the isolation of bioactive compounds from the aerial part of hemp (Cannabis sativa L.) assortment Helena
Sicari et al. Recovery of bergamot seed oil by supercritical carbon dioxide extraction and comparison with traditional solvent extraction
WO2019207554A1 (en) Extraction of compounds from cannabis biomass using food-grade solvent
WO2019211794A1 (en) Extraction using a microwave assisted extractor
Kulazynski et al. Supercritical fluid extraction of vegetable materials
CN105949057A (en) Preparation process for rosemary extract
Rodrigues et al. Obtaining high-quality oil from monguba (Pachira aquatica Aubl.) seeds by using supercritical CO2 process
Özcan et al. Comparative of physico-chemical properties of wheat germ oil extracted with cold press and supercritical co2 extraction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19759425

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19759425

Country of ref document: EP

Kind code of ref document: A1